Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Affymetrix Inc ("Affymetrix” or "the Company") (Nasdaq: AFFX) for
possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Thermo Fisher Scientific, Inc. (“Thermo Fisher”).
Click here to learn more about the investigation http://brodsky-smith.com/1019-affx-affymetrix-inc.html, or call: 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Affymetrix shareholders will receive only $14.00 in cash for each share of Affymetrix stock they own. The investigation concerns whether the Board of Affymetrix
breached their fiduciary duties to shareholders and whether Thermo Fisher is underpaying for the Company. The transaction may undervalue Affymetrix as it would significantly expand Thermo Fisher’s
antibody portfolio and adds genetic analysis capabilities. In addition, an analyst has set a $15.00 per share price target for Affymetrix stock.
If you own shares of Affymetrix and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will,
without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala
Cynwyd, PA 19004, by visiting http://brodsky-smith.com/1019-affx-affymetrix-inc.html, or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky &
Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders.
Attorney advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160115005915/en/